Annual report [Section 13 and 15(d), not S-K Item 405]

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.25.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
REVENUES:    
Product revenue, net $ 10,094 $ 7,768
COSTS AND EXPENSES:    
Cost of sales 7,765 4,741
Research and development 39,972 86,655
Selling, general and administrative 40,101 34,752
Asset impairment charges 58,957
 Total Operating Expenses 146,795 126,148
Operating loss (136,701) (118,380)
Grant income 2,594
Gain on change in fair value of warrant liabilities 6,150
Other (expense) income, net (2,079) 1,722
Net loss available to common stockholders $ (130,036) $ (116,658)
Net loss per common share, basic $ (176.60) $ (14,720.25)
Net loss per common share, diluted $ (176.60) $ (14,720.25)
Weighted average common shares outstanding, basic 736,339 7,925
Weighted average common shares outstanding, diluted 736,339 7,925